eFFECTOR Therapeutics (EFTRW) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Trading was temporarily halted for "EFTRW" at 08:04 AM with a stated reason of "News pending."April 4, 2024 | marketbeat.comeFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comeFFECTOR Therapeutics Inc. WarrantFebruary 4, 2024 | thestreet.comTrading was temporarily halted for "EFTRW" at 07:01 PM with a stated reason of "News pending."January 12, 2024 | marketbeat.comeFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024January 9, 2024 | finance.yahoo.comeFFECTOR updates Phase 1/2 data for breast cancer therapyDecember 8, 2023 | seekingalpha.comBuy Rating for eFFECTOR Therapeutics Backed by FDA Fast Track and Promising Clinical DataDecember 2, 2023 | markets.businessinsider.comeFFECTOR Therapeutics 10% owner SR One Capital Management discloses sale of 609,163 sharesNovember 30, 2023 | msn.comeFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerNovember 28, 2023 | finance.yahoo.comeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 27, 2023 | finanznachrichten.deeFFECTOR Therapeutics Stock (NASDAQ:EFTR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Inc.November 19, 2023 | thestreet.comeFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingNovember 15, 2023 | finance.yahoo.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceNovember 6, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid LeukemiaOctober 24, 2023 | finance.yahoo.com Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address DeFi Coin on Verge of Breakout! (Ad)The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! EFTRW Media Mentions By Week EFTRW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EFTRW News Sentiment▼0.000.54▲Average Medical News Sentiment EFTRW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EFTRW Articles This Week▼00▲EFTRW Articles Average Week Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DRTSW News BCTXW News FBIOP News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EFTRW) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
